Compare TNL & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | ABCL |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2006 | 2020 |
| Metric | TNL | ABCL |
|---|---|---|
| Price | $75.61 | $11.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $87.23 | $17.17 |
| AVG Volume (30 Days) | 712.8K | ★ 4.3M |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 4.66 | N/A |
| Revenue | ★ $4,021,000,000.00 | $75,128,000.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $5.26 | $7.12 |
| P/E Ratio | $15.30 | ★ N/A |
| Revenue Growth | 4.06 | ★ 160.56 |
| 52 Week Low | $60.34 | $2.75 |
| 52 Week High | $81.00 | $14.98 |
| Indicator | TNL | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 76.73 | 42.95 |
| Support Level | $71.82 | $10.61 |
| Resistance Level | $79.28 | $12.88 |
| Average True Range (ATR) | 2.09 | 0.87 |
| MACD | 1.15 | -0.07 |
| Stochastic Oscillator | 94.32 | 10.43 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.